Dyne Therapeutics, INC 8-K filings

Dyne Therapeutics has announced the pricing of a public offering of 10,500,000 shares of its common stock at $31.00 per share, expected to close around May 24, 2024.

Dyne Therapeutics reports positive clinical trial results for DYNE-101 in myotonic dystrophy type 1 (DM1) and DYNE-251 in Duchenne muscular dystrophy (DMD), showing significant improvements in key disease biomarkers and functional endpoints.

Dyne Therapeutics announced its first quarter 2024 financial results and provided updates on its ongoing clinical trials for DM1 and DMD, with additional data expected in the second half of the year.

Dyne Therapeutics has appointed John Cox as its new President and CEO, succeeding Joshua Brumm, who will now serve as a consultant to the company.

Dyne Therapeutics reported positive initial clinical data from their DM1 and DMD programs and secured $345 million in a public offering, extending their cash runway through 2025.